Here, treatment with DGLHD decreased the extent of fat accumulation and improved systemic and local metabolism, as evidenced by lowered fat content in liver and reduced levels of TC, TG, FFA, and increased adiponectin in vivo and in vitro, the latter of which benefits for improved insulin resistance and steatosis (Tilg and Moschen, 2006; Hardy et al., 2016). The gene discussed is INS; the disease is steatosis.